IL166413A0 - Use of and some novel imidazopyridines - Google Patents

Use of and some novel imidazopyridines

Info

Publication number
IL166413A0
IL166413A0 IL16641305A IL16641305A IL166413A0 IL 166413 A0 IL166413 A0 IL 166413A0 IL 16641305 A IL16641305 A IL 16641305A IL 16641305 A IL16641305 A IL 16641305A IL 166413 A0 IL166413 A0 IL 166413A0
Authority
IL
Israel
Prior art keywords
sup
formula
disclosed
compounds
imidazopyridines
Prior art date
Application number
IL16641305A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL166413A0 publication Critical patent/IL166413A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL16641305A 2002-08-14 2005-01-20 Use of and some novel imidazopyridines IL166413A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0202462A SE0202462D0 (sv) 2002-08-14 2002-08-14 Novel use
PCT/SE2003/001279 WO2004016611A1 (en) 2002-08-14 2003-08-13 Use of and some novel imidazopyridines

Publications (1)

Publication Number Publication Date
IL166413A0 true IL166413A0 (en) 2006-01-15

Family

ID=20288750

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16641305A IL166413A0 (en) 2002-08-14 2005-01-20 Use of and some novel imidazopyridines

Country Status (18)

Country Link
US (1) US7410966B2 (OSRAM)
EP (1) EP1539759B1 (OSRAM)
JP (1) JP2006503010A (OSRAM)
KR (1) KR20060005333A (OSRAM)
CN (1) CN100358893C (OSRAM)
AT (1) ATE370138T1 (OSRAM)
AU (1) AU2003251272A1 (OSRAM)
BR (1) BR0313461A (OSRAM)
CA (1) CA2495511A1 (OSRAM)
DE (1) DE60315674T2 (OSRAM)
ES (1) ES2290538T3 (OSRAM)
IL (1) IL166413A0 (OSRAM)
MX (1) MXPA05001581A (OSRAM)
NO (1) NO20051265L (OSRAM)
NZ (1) NZ538156A (OSRAM)
SE (1) SE0202462D0 (OSRAM)
WO (1) WO2004016611A1 (OSRAM)
ZA (1) ZA200500887B (OSRAM)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101022728B (zh) 2004-03-25 2012-08-08 詹森药业有限公司 咪唑化合物
WO2006009736A1 (en) 2004-06-17 2006-01-26 Wyeth Processes for preparing gonadotropin releasing hormone receptor antagonists
BRPI0512261A (pt) 2004-06-17 2008-02-26 Wyeth Corp antagonistas de receptor de hormÈnio liberador de gonadotropina
US7799778B1 (en) * 2005-01-12 2010-09-21 Alcon, Inc. 5-substituted 2-aminopyridine analogs for treating allergic and inflammatory diseases
KR20060087386A (ko) 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
EP1910358A2 (en) * 2005-07-14 2008-04-16 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
WO2007014707A1 (en) 2005-08-01 2007-02-08 F. Hoffmann-La Roche Ag Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents
BRPI0503681A (pt) 2005-08-19 2007-04-10 Fundacao Oswaldo Cruz compostos azóis usados como agentes tuberculostáticos e leishmanicidas, composições farmacêuticas contendo os mesmos, uso das respectivas composições farmacêuticas no tratamento ou inibição de doenças, bem como método de tratamento ou inibição de doenças
AR057525A1 (es) * 2005-10-03 2007-12-05 Astrazeneca Ab Compuestos inhibidores selectivos de gsk3 y un proceso para su preparacion
UY29825A1 (es) * 2005-10-03 2007-05-31 Astrazeneca Ab Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
US8334290B2 (en) 2005-10-31 2012-12-18 Merck Sharp & Dohme Corp. CETP inhibitors
JP5205276B2 (ja) * 2005-12-22 2013-06-05 ジ インスティテュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル 酵素阻害剤
WO2007083978A1 (en) * 2006-01-23 2007-07-26 Crystalgenomics, Inc. Imidazopyridine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same
ITMI20061581A1 (it) * 2006-08-04 2008-02-05 Univ Bari Ligandi del recettore beta-3 adrenergico e loro uso in terapia
CN101657446B (zh) * 2007-02-13 2013-05-15 Ab科学有限公司 合成作为激酶抑制剂的2-氨基噻唑化合物的方法
CN101679421A (zh) * 2007-03-30 2010-03-24 阿斯利康(瑞典)有限公司 新咪唑并[4,5-b]吡啶-7-甲酰胺704
WO2008121064A1 (en) * 2007-03-30 2008-10-09 Astrazeneca Ab New imidazo[4,5-b]pyridine-6-halo-7-aryl/heteroaryl compounds 705
WO2009001021A1 (en) * 2007-06-26 2008-12-31 Chroma Therapeutics Ltd. Imidazopyridine derivatives useful as enzyme inhibitors for the treatment of cell proliferative and autoimmune diseases
KR101703941B1 (ko) * 2008-11-10 2017-02-07 내셔날 헬스 리서치 인스티튜트 티로신 키나아제 억제제로서의 접합 이환 및 삼환 피리미딘 화합물
TWI461425B (zh) * 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
WO2012044043A2 (en) 2010-09-28 2012-04-05 Daewoong Pharmaceutical Co., Ltd. Novel method of preparing benzoimidazole derivatives
EP2809671B1 (en) * 2012-01-30 2016-01-13 Cephalon, Inc. Imidazo [4, 5 - b]pyridine derivatives as alk and jak modulators for the treatment of proliferative disorders
WO2013153539A1 (en) 2012-04-13 2013-10-17 Glenmark Pharmaceuticals S.A. Tricyclic compounds as tec kinase inhibitors
CN103724331A (zh) * 2012-10-11 2014-04-16 韩冰 一类治疗脑性瘫痪的化合物及其用途
CN103800328A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
GB201302927D0 (en) 2013-02-20 2013-04-03 Cancer Therapeutics Crc Pty Ltd Compounds
WO2014175370A1 (ja) * 2013-04-25 2014-10-30 塩野義製薬株式会社 ピロリジン誘導体およびそれらを含有する医薬組成物
CA2928721C (en) 2013-10-25 2020-12-22 Pharmacyclics Llc Use of ibrutinib for treating and preventing chronic graft versus host disease
EP3189041B1 (en) 2014-09-03 2021-04-28 Ctxt Pty Ltd Tetrahydroisoquinoline derived prmt5-inhibitors
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
WO2016034671A1 (en) 2014-09-03 2016-03-10 Ctxt Pty Ltd Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived prmt5-inhibitors
AU2016214492B2 (en) 2015-02-02 2020-05-07 Kancera Ab 2-phenyl-3H-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ROR1activity
MX2018002554A (es) 2015-08-31 2018-08-14 Pharmacyclics Llc Combinaciones de inhibidores de btk para tratar mieloma multiple.
GB201604027D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604020D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604031D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604029D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604022D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604030D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
EP3481824B1 (en) 2016-07-11 2021-10-20 Kancera AB 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity
US11660303B2 (en) 2016-07-11 2023-05-30 Kancera Ab 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity
EP3534938A2 (en) 2016-11-03 2019-09-11 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and a btk inhibitor
EP3787751A1 (en) 2018-05-03 2021-03-10 Juno Therapeutics, Inc. Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
EP4107151A1 (en) 2020-02-18 2022-12-28 Bayer Aktiengesellschaft Heteroaryl-triazole compounds as pesticides
CN113582988B (zh) * 2020-04-30 2025-09-09 正大天晴药业集团股份有限公司 吡啶并环类化合物及其医药用途
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985891A (en) 1973-02-03 1976-10-12 Boehringer Ingelheim Gmbh 2-Phenyl-imidazo (4,5-b)pyridines and salts thereof
DE3037464A1 (de) 1980-10-03 1982-05-19 Dr. Karl Thomae Gmbh, 7950 Biberach 6-hydroxy-2-phenyl-imidazo 4,5-b zu pyridine, ihre herstellung und diese sie enthaltende arzneimittel
US5296591A (en) * 1990-12-31 1994-03-22 Fujisawa Pharmaceutical Co., Ltd. Trifluoromethylketone derivatives, processes for preparation thereof and use thereof
US6943174B2 (en) * 2000-06-14 2005-09-13 Warner-Lambert Company 6,5-Fused bicyclic heterocycles
ATE310004T1 (de) * 2000-12-12 2005-12-15 Neurogen Corp Spiro(isobenzofuran-1,4'-piperidin)-3-one und 3h- spiroisobenzofuran-1,4'-piperidine

Also Published As

Publication number Publication date
EP1539759B1 (en) 2007-08-15
WO2004016611A1 (en) 2004-02-26
SE0202462D0 (sv) 2002-08-14
MXPA05001581A (es) 2005-04-25
CN1684964A (zh) 2005-10-19
DE60315674D1 (de) 2007-09-27
CA2495511A1 (en) 2004-02-26
NO20051265L (no) 2005-05-12
ZA200500887B (en) 2006-02-22
US7410966B2 (en) 2008-08-12
CN100358893C (zh) 2008-01-02
AU2003251272A1 (en) 2004-03-03
DE60315674T2 (de) 2008-06-19
ATE370138T1 (de) 2007-09-15
US20050261333A1 (en) 2005-11-24
EP1539759A1 (en) 2005-06-15
JP2006503010A (ja) 2006-01-26
ES2290538T3 (es) 2008-02-16
BR0313461A (pt) 2005-07-05
NZ538156A (en) 2006-09-29
KR20060005333A (ko) 2006-01-17

Similar Documents

Publication Publication Date Title
IL166413A0 (en) Use of and some novel imidazopyridines
ZA200501098B (en) Novel use of benzothiazole derivatives
IL150635A0 (en) Novel use of phenylheteroalkylamine derivatives
TNSN03144A1 (en) Pyrrolopyrimidines as protein kinase inhibitors
AU2003298094A1 (en) Medicinal arylethanolamine compounds
GB0112348D0 (en) Compounds
MXPA05011207A (es) Uso de derivados de 2,4-dihidro-[1,2,4]triazol-3-tiona como inhibidores de la enzima mieloperoxidasa (mpo).
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
MY157949A (en) Thioxanthine derivatives as myeloperoxidase inhibitors
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
MY133527A (en) Isoquinoline derivatives
PL1697394T3 (pl) Inhibitory COMT
MY160429A (en) 2, 5-disubstituted 3-mercaptopentanoic acid
IL150640A0 (en) Novel use of phenylheteroalkylamine derivatives
BRPI0415546A (pt) composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, e de distúrbios
YU30602A (sh) Primena 2-amino-3,4-dihidro-hinazolina za proizvodnju leka za lečenje ili profilaksu bolesti koje su prouzrokovane ishemičnim stanjima
DE60233578D1 (de) Phosphorenthaltende Verbindugnen mit antithrombitische Wirkung
SE0201193D0 (sv) Novel use
SG135051A1 (en) Azaindoles